Volume 17, Number 12—December 2011
Rift Valley and West Nile Virus Antibodies in Camels, North Africa
Highlight and copy the desired format.
|EID||El-Harrak M, Martín-Folgar R, Llorente F, Fernández-Pacheco P, Brun A, Figuerola J, et al. Rift Valley and West Nile Virus Antibodies in Camels, North Africa. Emerg Infect Dis. 2011;17(12):2372-2374. https://dx.doi.org/10.3201/eid1712.110587|
|AMA||El-Harrak M, Martín-Folgar R, Llorente F, et al. Rift Valley and West Nile Virus Antibodies in Camels, North Africa. Emerging Infectious Diseases. 2011;17(12):2372-2374. doi:10.3201/eid1712.110587.|
|APA||El-Harrak, M., Martín-Folgar, R., Llorente, F., Fernández-Pacheco, P., Brun, A., Figuerola, J....Jiménez-Clavero, M. (2011). Rift Valley and West Nile Virus Antibodies in Camels, North Africa. Emerging Infectious Diseases, 17(12), 2372-2374. https://dx.doi.org/10.3201/eid1712.110587.|
To the Editor: Different arboviral diseases have expanded their geographic range in recent times. Of them, Rift Valley fever, West Nile fever, and African horse sickness are of particular concern. They are endemic in sub-Saharan Africa but occasionally spread beyond this area. Trade and transport of animals and animal products, along with wildlife movements, are considered the driving factors in the spread of these pathogens.
In wide regions of Africa, 1-humped camels (Camelus dromedarius) are valuable livestock appreciated as a meat source and as a means for transportation of goods. Camels are susceptible to infection by Rift Valley fever virus (RVFV), West Nile virus (WNV), and African horse sickness virus (AHSV), although their epidemiologic role in these diseases is uncertain (1–3). Movements of camels across the Sahara Desert could carry these pathogens to northern Africa. To test this hypothesis, we conducted a serologic survey in 1-humped camels intercepted at different points by the Moroccan Veterinary Services in 2009. The camels were coming from the southeastern part of the Sahara Desert going to the northwest.
Serum samples were obtained in Smara-Laayoune, Dakhla, and Tata (Table). Most samples (71 of 100 total samples) were from male camels. Samples were also grouped by age of the camels (Table). RVFV antibodies were detected by using a competitive ELISA (4), and samples yielding positive ELISA results were confirmed by virus-neutralization test. WNV-specific antibodies were detected by ELISA (5), and positive results were confirmed by virus-neutralization test. AHSV-specific antibodies were detected by using the ELISA prescribed by the World Organisation for Animal Health.
Fifteen of 100 samples were positive for RVFV-specific antibodies by competitive ELISA, all of which were confirmed by virus-neutralization test, with neutralization titers ranging from 40 to 1,280 (geometric mean titer = 229). With regard to WNV antibodies, the ELISA detected 44 positive samples and 1 doubtful sample, of which 29 were confirmed as positive by virus-neutralization test (virus-neutralization test titers ranging from 10 to 640; geometric mean titer = 20). As for AHSV antibodies, none of the samples was positive by ELISA. Prevalence data were analyzed by generalized linear model with locality (Dakhla or Smara), sex, and age as fixed factors. No differences by origin or sex were found in prevalence for WNV (p>0.14) but antibodies were more prevalent in camels >3 years of age (χ2 = 14.04, 3 df, p = 0.003). No differences in prevalence of RVFV antibodies were found by sex (p = 0.29), but prevalence was higher in Smara (χ2 = 3.74, p = 0.05) and among camels >6 years of age (χ2 = 8.37, df = 3, p = 0.04) (Table). We also examined the co-occurrence of antibodies to RVFV and WNV. Of 15 RVFV-positive samples, 12 were also positive for WNV antibodies, and 12 of 29 WNV-positive samples were also positive for RVFV (χ2 = 8.37, df = 1, p < 0.05).
Antibodies to 2 zoonotic arboviruses, i.e., RVFV and WNV, were present in camels moving to the northwestern part of the Sahara Desert, and antibodies to AHSV were absent in the populations examined. Despite the higher percentage of seropositivity for WNV than for RVFV, the epidemiologic consequence of RVFV-specific antibodies in this population could be higher than that for WNV antibodies. Camels can act as reservoir hosts for RVFV (6) but are unlikely to do so for WNV, which cycles between mosquitoes and wild birds with mammals usually being dead-end hosts. High prevalence of antibodies to RVFV in camels has been described in different sub-Saharan and Sahelian countries (7–9). Camels have been involved in the spread of disease in some instances (10). Immunity to RVFV indicates previous infection. Our results showed that seroprevalence of RVFV was higher among older than younger camels, indicating that contact could have occurred some years ago. Nevertheless, these populations should be monitored for RVFV and other arboviroses because these are known to reemerge under certain circumstances in locations where they have occurred in the past.
The results of this study support that camels moving across the Sahara have contact with RVFV and WNV, and frequently the same animals have been infected by both agents. In a particularly dry environment such as the desert, particular attention should be paid to singular wet areas such as oases. The presence of water in these areas results in an abundance of competent mosquitoes and hosts, which in turn makes these viruses likely to cycle and infect domestic animals such as camels coming to drink and rest.
We thank the Ministry of Agriculture of Morocco for technical assistance on sample collection.
This research was supported by Biopharma and INIA-MARM agreement no. CC08-020.
- Dauphin G, Zientara S, Zeller H, Murgue B. West Nile: worldwide current situation in animals and humans. Comp Immunol Microbiol Infect Dis. 2004;27:343–55.
- Elfadil AA, Hasab-Allah KA, Dafa-Allah OM. Factors associated with Rift Valley fever in south-west Saudi Arabia. Rev Sci Tech. 2006;25:1137–45.
- Mellor PS, Hamblin C. African horse sickness. Vet Res. 2004;35:445–66.
- Martín-Folgar R, Lorenzo G, Boshra H, Iglesias J, Mateos F, Borrego B, Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization. MAbs. 2010;2:275–84.
- Sotelo E, Llorente F, Rebollo B, Camuñas A, Venteo A, Gallardo C, Development and evaluation of a new epitope-blocking ELISA for universal detection of antibodies to West Nile virus. J Virol Methods. 2011;174:35–41.
- Scott GR, Coackley W, Roach RW, Cowdy NR. Rift Valley fever in camels. J Pathol Bacteriol. 1963;86:229–31.
- Mariner JC, Morrill J, Ksiazek TG. Antibodies to hemorrhagic fever viruses in domestic livestock in Niger: Rift Valley fever and Crimean-Congo hemorrhagic fever. Am J Trop Med Hyg. 1995;53:217–21.
- Eisa M. Preliminary survey of domestic animals of the Sudan for precipitating antibodies to Rift Valley fever virus. J Hyg (Lond). 1984;93:629–37.
- Olaleye OD, Tomori O, Schmitz H. Rift Valley fever in Nigeria: infections in domestic animals. Rev Sci Tech. 1996;15:937–46.
- Abd el-Rahim IH, Abd el-Hakim U, Hussein M. An epizootic of Rift Valley fever in Egypt in 1997. Rev Sci Tech. 1999;18:741–8.
- Table. Results of testing of camels for virus antibodies, by location, age group, and sex of camels examined, North Africa, 2009
Please use the form below to submit correspondence to the authors or contact them at the following address:
Miguel Ángel Jiménez-Clavero, Centro del Investigación en Sanidad Animal (INIA), Ctra Algete- El Casar s/n, 28130, Valdeolmos, Spain
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 18, 2011
- Page last updated: November 18, 2011
- Page last reviewed: November 18, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)